Id: | acc4125 |
Group: | 1sens |
Protein: | VEGFR2 |
Gene Symbol: | Kdr |
Protein Id: | P35918 |
Protein Name: | VGFR2_MOUSE |
PTM: | phosphorylation |
Site: | Tyr951 |
Site Sequence: | RFRQGKDYVGELSVDLKRRLD |
Disease Category: | Endocrine and metabolic diseases |
Disease: | Diabetes Mellitus |
Disease Subtype: | diabetic kidney disease |
Disease Cellline: | |
Disease Info: | |
Drug: | angiopoietin-1 |
Drug Info: | Angiopoietin - 1 is a protein that plays a crucial role in blood vessel formation and vascular stability. It is important in physiological and pathological angiogenesis processes. |
Effect: | modulate |
Effect Info: | "Supplementation of angiopoietin-1 in diabetic mice increased the phosphorylation of Tie-2 and the level of soluble VEGFR1, accompanied by a decrease in the phosphorylation level of VEGFR2 and an increase in the phosphorylation level of endothelial nitric oxide synthase Ser(1177), along with a decrease in the phosphorylation of VEGFR2 and an increase in the phosphorylation of endothelial nitric oxide synthase Ser(1177). " |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 24009238 |
Sentence Index: | 24009238_7 |
Sentence: | "Furthermore, angiopoietin-1 repletion in diabetic mice increased Tie-2 phosphorylation, elevated soluble VEGFR1, and was paralleled by a decrease in VEGFR2 phosphorylation and increased endothelial nitric oxide synthase Ser(1177) phosphorylation." |
Sequence & Structure:
MESKALLAVALWFCVETRAASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLEVIILVGTAVIAMFFWLLLVIVLRTVKRANEGELKTGYLSIVMDPDELPLDERCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCKTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRGKRNEFVPYKSKGARFRQGKDYVGELSVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEASEELYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHEDPNQRPSFSELVEHLGNLLQANAQQDGKDYIVLPMSETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISHYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDSQTDSGMVLASEELKTLEDRNKLSPSFGGMMPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSDEAGLLKMVDAAVHADSGTTLRSPPV
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
Y | 949 | D | Ovarian cancer | Phosphorylation | 33726754 |
K | 856 | P | Cancer and age-related macular degeneration | Methylation | 24300896 |
K | 861 | P | Cancer and age-related macular degeneration | Methylation | 24300896 |
K | 1041 | P | Cancer and age-related macular degeneration | Methylation | 24300896 |
R | 817 | P | Cancer and age-related macular degeneration | Methylation | 24300896 |
R | 1115 | P | Cancer and age-related macular degeneration | Methylation | 24300896 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.